Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if Regorafenib in combination with best supportive
care will slow down tumor progression and result in increased survival in patients with
metastatic colorectal cancer.